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Neuregulin 1 (NRG1) is linked to an increased risk of developing schizophrenia and
cannabis dependence. Mice that are hypomorphic for Nrg1 (Nrg1 HET mice) display
schizophrenia-relevant behavioral phenotypes and aberrant expression of serotonin and
glutamate receptors. Nrg1 HET mice also display idiosyncratic responses to the main
psychoactive constituent of cannabis, 9 -tetrahydrocannabinol (THC). To gain traction
on the molecular pathways disrupted by Nrg1 hypomorphism and Nrg1-cannabinoid
interactions we conducted a proteomic study. Adolescent wildtype (WT) and Nrg1 HET
mice were exposed to repeated injections of vehicle or THC and their hippocampi were
submitted to 2D gel proteomics. Comparison of WT and Nrg1 HET mice identified proteins
linked to molecular changes in schizophrenia that have not been previously associated
with Nrg1. These proteins are involved in vesicular release of neurotransmitters such
as SNARE proteins; enzymes impacting serotonergic neurotransmission, and proteins
affecting growth factor expression. Nrg1 HET mice treated with THC expressed a
distinct protein expression signature compared to WT mice. Replicating prior findings,
THC caused proteomic changes in WT mice suggestive of greater oxidative stress
and neurodegeneration. We have previously observed that THC selectively increased
hippocampal NMDA receptor binding of adolescent Nrg1 HET mice. Here we observed
outcomes consistent with heightened NMDA-mediated glutamatergic neurotransmission.
This included differential expression of proteins involved in NMDA receptor trafficking
to the synaptic membrane; lipid raft stabilization of synaptic NMDA receptors; and
homeostatic responses to dampen excitotoxicity. These findings uncover novel proteins
altered in response to Nrg1 hypomorphism and Nrg1-cannabinoid interactions that
improves our molecular understanding of Nrg1 signaling and Nrg1-mediated genetic
vulnerability to the neurobehavioral effects of cannabinoids.
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INTRODUCTION
Neuregulin 1 (Nrg1) is a neurotrophic factor that mediates its
effects by binding ErbB receptor tyrosine kinases. Nrg1 regu-
lates axonal guidance, myelination, and GABAergic and gluta-
matergic neurotransmission (Mei and Xiong, 2008). The human
NRG1 gene has been linked to schizophrenia by genetic studies
(Stefansson et al., 2002; Ayalew et al., 2012) and altered expression
of NRG1 isoforms has been measured in schizophrenia patients
(Hashimoto et al., 2004; Chong et al., 2008; Marballi et al., 2012;
Weickert et al., 2012). NRG1 variants have been associated with
dysfunction in a number of schizophrenia-relevant “endopheno-
types” including sensorimotor gating as measured by prepulse
inhibition of startle (PPI) (Hong et al., 2008; Roussos et al., 2011;
Greenwood et al., 2012) and working memory (Chong et al.,
2008).
Use of transgenic murine models can be useful in explor-
ing the role of Nrg1 in molecular neurobiology and behavior.
The most extensively studied mouse model of Nrg1 dysfunction
is the Nrg1 transmembrane heterozygous (Nrg1 HET) mouse
which exhibits locomotor hyperactivity and protocol-dependent
PPI deficits (Stefansson et al., 2002; Karl et al., 2007; Spencer
et al., 2012). These mice display altered anxiety profiles, inhib-
ited preference for social novelty and increased levels of aggressive
social interaction as well as impaired performance in novel object
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recognition and fear conditioning paradigms (Karl et al., 2007;
O’Tuathaigh et al., 2007, 2008; Duffy et al., 2010; Desbonnet et al.,
2012). Hypo-phosphorylation of the NR2B subunit of the NMDA
receptor is observed inNrg1HETmice (Bjarnadottir et al., 2007).
Together, these findings provide some clues of the molecular and
neurobiological alterations that mediate the aberrant behavioral
phenotypes exhibited by Nrg1 HET mice.
Adolescence is particularly relevant to schizophrenia given the
onset of the disorder typically occurs in late adolescence. During
adolescence there exists significant synaptic pruning and a shift
between utilization of mesolimbic and mesocortical areas of the
brain which indicates a high level of neural development dur-
ing this period (Giedd et al., 1999; Spear, 2000; Casey et al.,
2008). Nrg1 HET mice display developmentally-specific neurobi-
ological and behavioral phenotypes, for example, adolescentNrg1
HET mice have reduced 5-HT2A receptor expression in the insu-
lar and cingulate cortices (Long et al., 2013) in contrast to the
global increase in 5HT2A receptor expression observed in adult
Nrg1 HET mice relative to controls (Dean et al., 2008). Nrg1
HETmice display an enhanced stress-induced release of corticos-
terone relative to wildtype (WT) controls at 3–4 months of age,
an effect that disappears by 5–6 months (Chesworth et al., 2012).
Together these findings point toward the Nrg1 HET mouse being
a particularly suitable model for demonstrating a role for Nrg1 in
developmental stage-specific neurobehavioral alterations.
Drug dependence and schizophrenia are comorbid disorders
that may have common genetic and neurobiological substrates.
Genetic vulnerability is thought to explain why only a subset
of cannabis users become dependent on cannabis or develop
psychosis. A recent study demonstrated that NRG1 increased
the risk of cannabis dependence in African-Americans (Han
et al., 2012). We have shown Nrg1 HET mice display distinct
schizophrenia-relevant neurobehavioral responses to cannabi-
noids, including the main psychoactive constituent of cannabis,
9-tetrahydrocannabinol (THC). Acute cannabinoid exposure
promoted PPI facilitation in Nrg1 HET mice but PPI deficits in
WT mice (Boucher et al., 2007a, 2011). Nrg1 genotype also mod-
ulated tolerance to the effects of cannabinoids, with Nrg1 HET
mice developing tolerance more rapidly to locomotor suppres-
sion and hypothermia than WT mice, but conversely showing a
lack of tolerance to cannabinoid-induced anxiety unlikeWTmice
(Boucher et al., 2011). The acute and repeated effects of cannabi-
noids correlate with selective changes in Fos transcription factor
expression in the lateral septum of Nrg1 HET mice that were
not observed in WT mice (Boucher et al., 2007b, 2011). In ado-
lescence Nrg1 modulated the effects of repeated THC exposure
on the expression of neurotransmitter receptors relevant to the
pathophysiology of schizophrenia (i.e., CB1, NMDA, and 5-HT2A
receptors) (Long et al., 2013).
The hippocampus may be an important region for Nrg1-
cannabinoid interactions as both endocannabinoid and Nrg1-
ErbB systems are highly expressed in this brain region
(Herkenham et al., 1990; Tsou et al., 1998; Vullhorst et al., 2009).
We have observed increased brain transcriptional activity in the
lateral septum at baseline and following cannabinoid exposure
in Nrg1 HET mice, both of which might reflect downstream
effects of aberrant activity in the hippocampus as part of the
septohippocampal system. Therefore, molecular changes in the
hippocampus may subserve the distinct neurobehavioral pheno-
types displayed byNrg1HETmice as well as their altered response
to THC. Of particular interest is our observation that adolescent
THC–treated Nrg1 HET mice display increased NMDA recep-
tor expression in the hippocampus, something not observed in
THC-treated WT mice (Long et al., 2013). Here we aim to gain
some traction on the molecular mechanisms involved in the aber-
rant phenotypes exhibited by Nrg1 HET mice at baseline and
when exposed to THC using a proteomic approach which allows
us to detect changes in hundreds of different proteins in the
hippocampus.
MATERIALS AND METHODS
ANIMALS AND DRUG TREATMENT
At the commencement of the study adolescent male Nrg1 HET
mice andWT littermates (C57/BL6 background strain) were at an
age of post-natal day (PND) 31 ± 2. The study was restricted to
male mice as maleNrg1 HETmice appear more vulnerable to the
effects of cannabinoids (Long et al., 2010). Mice were pair-housed
at Neuroscience Research Australia with limited environmen-
tal enrichment [certified polycarbonate mouse igloo (Bioserv,
USA) and a metal ring in the cage lid] under a 12 h light/dark
schedule (lights on 08:30 h) and genotyped as previously detailed
(Karl et al., 2007). Food and water were available ad libitum.
THC (THC Pharm GmbH, Germany) was suspended in a 1:1:18
mixture of ethanol:Tween 80:0.9% saline and injected intraperi-
toneally at a volume of 10ml/kg. Mice were injected daily with
either 10mg/kg of THC or vehicle for 21 days. During this time
mice were repeatedly behaviorally tested, the results of which
are published elsewhere (Long et al., 2013). Two days following
the completion of treatment, the mice (n = 8) were euthanized
by cervical dislocation, with both hippocampi dissected out and
snap frozen on dry ice for proteomic analysis. Research and ani-
mal care procedures were approved by the University of New
South Wales Animal Care and Ethics Committee and were in
accordance with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes.
PROTEIN EXTRACTION
Protein extraction was performed using a protocol optimized for
cytosolic proteins (Quinn et al., 2008). Hippocampal tissue was
homogenized in buffer consisting of 7M urea, 2M thiourea, 1%
C7bZO and 40mM Tris, sonicated and pelleted. The supernatant
was reduced and alkylated in 5mM tributylphosphine (TBP)
and 10mM acrylamide monomer and quenched using 10mM
dithiothreitol (DTT). The mixture was acidified to pH 6.0 using
concentrated citric acid and precipitated with acetone. The pre-
cipitate was pelleted, air-dried and resuspended in 7M urea, 2M
thiourea and 1% C7bZO.
2D GEL ELECTROPHORESIS
Sample protein concentration was determined using the Bradford
Protein Assay (Thermoscientific, USA). Immobilized pH gra-
dient strips (IPG strips; 11 cm, pH 4–7) were rehydrated with
samples containing 600μg protein, and samples were sep-
arated by isoelectric point (pI). Strips were equilibrated in
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SDS equilibration buffer and loaded onto SDS-PAGE gradient
gels (8–16%, 10 × 15 cm) and separated by molecular weight
using an ElectrophoretIQ3 system (30mA/gel, 25◦C for 110min;
Proteome Systems, Australia). Gels were fixed with methanol
[25% (v/v)] and acetic acid [10% (v/v)] and visualized using
Flamingo Fluorescent gel stain (BioRad, USA).
IMAGE ANALYSIS
Gels were analyzed using Phoretix 2D Expression software (Non-
linear Dynamics Ltd, UK). Averaged gels were created for each
experimental group and averaging parameters were set at 70%.
Single factor ANOVAs (p < 0.05) of spot volume were performed
to determine the effect of genotype in vehicle-treated animals, the
effect of THC administration in WT mice and the effect of THC
administration in Nrg1 HET mice.
MASS SPECTROMETRY AND PROTEIN IDENTIFICATION
Protein spots that were identified as significantly altered were
digested in 12.5 ng/mL trypsin (Roche, USA) and 25 nM
NH4HCO3/0.1% trifluroacetic acid and purified using C18 purifi-
cation tips (Eppendorf, Germany) before being eluted in 3μL of
matrix solution. Spots were analyzed using an Applied Biosystems
QSTAR MALDI-TOF mass spectrometer (Australian Proteome
Analysis Facility, University of Sydney). MALDI spectra were
matched against the Swiss-Prot database using the MASCOT
search engine with matches determined by molecular weight
search score (MWS) and sequence coverage in conjunction with
pI and molecular weight as estimated from gels.
IMMUNOBLOTTING
Ten ug of protein per lane was separated by electrophoresis using
10% precast NuPage gels (Invitrogen, USA) and run at 110 V
for 2 h. The samples were transferred to PVDF membranes.
Membranes were sequentially incubated with Syntaxin-1A
antibody (Sigma Aldrich, USA 1:1500) then swine anti-rabbit
secondary antibody (DAKO, Australia, 1:200) and rabbit
Peroxidase-Anti-Peroxidase (Sigma-Aldrich, USA 1:200) and
DAB (DAKO, Australia). Membranes were stripped using Re-blot
plus strong antibody stripping solution (Millipore, Australia)
and incubated sequentially with Abcam rat monoclonal YL1/2
α-tubulin (TUBA) antibody (Sapphire Biosciences Pty Ltd,
Australia, 1:) then anti-rat IgG (HþL) horseradish peroxidase
conjugate (Santa Cruz Biotechnology Inc, USA) and visualized
using a Syngene G:Box.
RESULTS
Here we present the results of a hippocampal proteomic study
conducted on adolescent Nrg1 HET mice and WT control mice
treated with or without THC. The averaged gels for WT vehi-
cle, WT THC, Nrg1 HET vehicle and Nrg1 HET THC contained
870, 821, 761, and 742 spots respectively. 26 spots were sig-
nificantly different between WT vehicle and Nrg1 HET vehicle
mice. Of these spots, 17 proteins were identified using MALDI-
TOF MS and the fold changes from control WT mice are
listed in Table 1. Figure 1A shows a representative 2D gel image
of protein expression in the hippocampus of a WT mouse
administered vehicle. Normalized spot volumes are depicted
for three representative proteins are shown in Figure 1B, i.e.,
syntaxin 1A (STX1A), beta-soluble N-ethylmaleimide-sensitive
factor attachment protein (β-SNAP) and glypican 6 (GPC6).
Western blotting results confirmed Nrg1 HET mice displayed
increased expression of STX1A compared to WT mice (see
Figure 1B).
THC induced changes in 28 spots and 23 spots inWT andNrg1
HET mice respectively relative to vehicle-treated mice within
the same genotype. From these comparisons, 4 and 10 pro-
teins were identified as being significantly altered by THC expo-
sure in adolescent WT and Nrg1 HET mice and fold changes
are listed in Table 2 (relative to WT mice treated with vehi-
cle) and 3 (relative to Nrg1 HET mice treated with vehicle)
respectively. Figure 2A shows a representative 2D gel image
of protein expression in the hippocampus of an adolescent
WT mouse administered repeated THC injections. Normalized
spot volumes are depicted for 3 representative proteins in
Figure 2B, i.e., glutathione S-transferase Mu 2 (GSTM2), cal-
retinin (CALB2) and ADP-ribosylation factor-like protein 1
(ARL1). Nrg1 HET mice treated with THC displayed a dis-
tinct protein expression profile to WT mice exposed to the
drug. Figure 3A shows a representative 2D gel image of pro-
tein expression in the hippocampus of an adolescent Nrg1
HET mouse administered repeated THC. Normalized spot vol-
umes of three representative proteins are depicted in Figure 3B,
i.e., G-protein-signaling modulator 2 (GPSM2), apolipoprotein
A1 (APOA1) and N-acyl-phosphatidylethanolamine-hydrolyzing
phospholipase D (NAPEPLD).
DISCUSSION
Nrg1 HET mice, displayed altered expression of a number of
proteins involved in the vesicular release of neurotransmitters
including STX1A, syntaxin 7 (STX7) and β-SNAP; seroton-
ergic neurotransmission including tryptophan 5-hydroxylase 1
(TPH1) and serotonin N-acetyltransferase (AA-NAT); growth
factor expression and regulation including secreted protein acidic
and rich in cysteine (SPARC) and GPC6, and; cell survival and
regulators of inflammatory cytokines including cell death reg-
ulator Aven (AVEN), TNFAIP3-interacting protein 2 (ABIN2)
and regulator of G-protein signaling 10 (RGS10). We replicated
prior findings in rodents without genetic modification show-
ing THC reduced the hippocampal expression of GSTM2 and
affected the expression of heat shock proteins (here HSPA4). We
also identified novel proteins changed in response to repeated
THC exposure, that is, CALB2 and ARL1. Unlike WT mice, Nrg1
HET mice administered THC displayed altered expression of
proteins involved in NMDA receptor trafficking to the synaptic
membrane including GPSM2; lipid raft stabilization of recep-
tors at the synaptic membrane including flotillin-1 (FLOT1);
homeostatic responses to dampen excessive glutamatergic trans-
mission, including NAPEPLD, and excitotoxicity and apoptosis
including programmed cell death protein 2 (PCD2). Figure 4 is
a schematic proposing an overview of the proteins found to have
altered expression in the current study and their potential func-
tional significance. Proteomics may produce false positives and
fold changes < 1.5 should be interpreted cautiously. Nevertheless,
these results, while suggestive rather than conclusive, provide
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FIGURE 1 | Adolescent hippocampal proteomics comparing adolescent
vehicle-treated WT and Nrg1 HET mice. (A) Representative 2DE gel
images showing positions of significantly altered protein spots [the
horizontal axis split by isoelectric point, vertical axis split by molecular
weight; STX1A (spot 11755); TPH1 (spot 11967); β-SNAP (spot 11358);
SPARC (spot 11646); GPC6 (spot 11294)]; and (B) Exemplar normalized
volumes of altered proteins i.e., STX1A, β-SNAP and GPC6. The inset
for STX1A shows immunoblots against STX1A and loading control
alpha-tubulin (TUBA), confirming greater expression of STX1A in Nrg1 HET
versus WT mice.
a platform for future work to confirm and more fully charac-
terize the role of various novel proteins in the effects of Nrg1
hypomorphism, THC and Nrg1-THC interactions.
DISTINCT PROTEIN EXPRESSION IN THE HIPPOCAMPUS OF
ADOLESCENT Nrg1 HET AND WT MICE
Disordered neurotransmission is involved in the pathophysiol-
ogy of schizophrenia and NRG1, a schizophrenia susceptibility
gene, regulates neurotransmitter receptor expression and synap-
tic plasticity (Mei and Xiong, 2008). Here we provide evidence
that heterozygous deletion of Nrg1 alters numerous proteins
involved in the transport, fusion and recycling of synaptic vesi-
cles, all processes critical to neurotransmitter release and synaptic
function. The soluble N-ethylmaleimide-sensitive fusion attach-
ment protein receptor (SNARE) complex regulates exocytotic
release of neurotransmitters from presynaptic terminals and alter-
ations in SNARE mRNA and protein is observed in post-mortem
schizophrenia brain (Ramakrishnan et al., 2012). Here we show
for the first time that Nrg1 hypomorphism alters the expression
of various SNARE proteins including STX1A, STX7, and β-SNAP.
STX1A was increased almost three-fold in Nrg1 HETmice rel-
ative to WT controls and this change was confirmed by Western
blot analysis. Located within the pre-synaptic membrane, STX1A
combines with 25 kDa synaptosome-associated protein SNAP25
and vesicle-associated membrane protein 2 to form a complex
that drives vesicle and presynaptic membrane fusion necessary
for neurotransmitter exocytosis. Concordant with our findings in
Nrg1 HET mice, STX1A is upregulated in the hippocampus and
cingulate cortex of schizophrenic patients (Gabriel et al., 1997;
Honer et al., 1997; Sokolov et al., 2000; Clark et al., 2007). We also
demonstrate here that STX7, a member of an endocytic SNARE
complex, was upregulated in Nrg1 HET mice compared to WT
mice. STX7 mediates endocytic trafficking from early endosomes
to late endosomes, and is necessary for fusion of late endo-
somes to lysosomes (Mullock et al., 2000; Nakamura et al., 2000).
β-SNAP displayed an almost 9-fold reduction in expression in
Nrg1HETmice compared to WTmice. β-SNAP belongs to a class
of proteins known as SNAPs, which form complexes with SNARE
proteins to assist with membrane fusion before being dissoci-
ated by the ATPase N-ethylmaleimide-sensitive factor. In contrast
to other SNAPs, β-SNAP is localized to neural tissue, including
hippocampal cells (Schiavo et al., 1995).
Nrg1 HET mice also displayed altered expression of several
proteins involved in protein transport between the endoplas-
mic reticulum (ER) and Golgi apparatus. These included β-
SNAP, dynactin subunit 2 (DCTN2) and ADP-ribosyl cyclase 2
(BST-1). Transport of protein from the ER to the Golgi is impor-
tant to protein sorting and the dispatch of protein to cellular
Frontiers in Cellular Neuroscience www.frontiersin.org February 2013 | Volume 7 | Article 15 | 5
Spencer et al. Nrg1 and Nrg1-THC proteomics
Ta
b
le
2
|A
d
o
le
sc
en
t
h
ip
p
o
ca
m
p
al
p
ro
te
o
m
ic
s
co
m
p
ar
in
g
ad
o
le
sc
en
t
W
T
m
ic
e
tr
ea
te
d
w
it
h
ve
h
ic
le
an
d
T
H
C
.
S
p
o
t
n
u
m
b
er
P
ro
te
in
n
am
e
A
b
b
re
vi
at
io
n
U
n
iP
ro
t
ac
ce
ss
io
n
n
u
m
b
er
P
I
M
as
s
(D
a)
M
W
S
N
o.
o
f
p
ep
ti
d
es
m
at
ch
ed
%
se
q
co
ve
r
Fo
ld
ch
an
ge
T
-t
es
t
(p
)
O
X
ID
A
T
IO
N
R
E
G
U
LA
T
IO
N
P
R
O
T
E
IN
S
11
41
8
G
lu
ta
th
io
ne
S
-t
ra
ns
fe
ra
se
M
u
2
G
ST
M
2
P
15
62
6
6.
9
25
,7
17
73
5
20
−1
.7
59
0.
02
67
9
11
76
9
H
ea
t
sh
oc
k
70
kD
a
pr
ot
ei
n
4
H
S
PA
4
Q
61
31
6
5.
15
94
,1
33
95
8
14
2.
13
7
0.
04
30
5
O
T
H
E
R
11
10
3
C
al
re
tin
in
C
A
LB
2
Q
08
33
1
4.
94
31
,3
73
66
4
21
−1
.7
48
0.
03
04
5
11
67
7
A
D
P-
rib
os
yl
at
io
n
fa
ct
or
-li
ke
pr
ot
ei
n
1
A
R
L1
P
61
21
1
5.
63
20
,4
12
57
3
20
−2
.8
69
0.
04
05
1 locations. An increased expression of DCTN2 was also observed
in Nrg1 HET mice. DCTN2 is a functional subunit of dynactin, a
component of the dynein-dynactin system. DCTN2 overexpres-
sion inhibits dynactin, and therefore dynein functions such as
dynein-dependent maintenance of membrane organelle distribu-
tion (Burkhardt et al., 1997). DCTN2 is associated with syntaxin
18, an ER-localized SNARE involved in membrane trafficking
between the ER and Golgi (Arasaki et al., 2006). BST-1, which
was downregulated in Nrg1 HET mice, is also implicated in ER
to Golgi transport as it suppressed such trafficking in yeast cells
(Sompol et al., 2011).
Previous studies suggest thatNrg1 hypomorphism affects sero-
tonergic neurotransmission, by altering the expression of 5-HT2A
receptors and the serotonin transporter in various brain regions
of both adolescent and adult mice (Dean et al., 2008; Long et al.,
2013). The observation that Nrg1 HET mice had reduced expres-
sion of TPH1 and increased level of AA-NAT is consistent with
this notion. TPH1 is one of two isoforms of the enzyme involved
in the rate-limiting synthesis of serotonin. Polymorphism in
TPH1 is associated with increased risk for various psychiatric
disorders including schizophrenia and bipolar disorder (Saetre
et al., 2010; Seifuddin et al., 2012) and varies with neurodevel-
opment with peaks at PND 21 before decreasing in adulthood
(Nakamura et al., 2006). Given the autocrine role of serotonin
in guiding the development of serotonergic neurons (Gaspar
et al., 2003), reduced TPH1 expression in adolescent Nrg1 HET
mice may reflect aberrant development of serotonergic brain
circuitry in these mice. AA-NAT, which converts serotonin to N-
acetylserotonin, was also upregulated in the hippocampus ofNrg1
HET mice. This role of this enzyme is well characterized in the
pineal gland due to its involvement in melatonin synthesis and
sleep-wake cycles (Zheng and Cole, 2002). However, the function
of AA-NAT in other brain regions including the hippocampus is
poorly understood. AA-NAT is expressed in a non-diurnal depen-
dent manner in the hippocampus (Uz et al., 2002) and promotes
hippocampal neuroprogenitor cell proliferation in mice (Sompol
et al., 2011).
Given that Nrg1 is a neurotrophic factor it is not entirely sur-
prising that Nrg1 HET mice display altered expression of the
growth factor fibroblast growth factor 14 (FGF14) and regulators
of growth factor protein expression, including SPARC and GPC6.
FGF14 knockout mice, like Nrg1 HET mice, display locomotor
hyperactivity, spatial learning deficits and impaired hippocam-
pal long-term potentiation associated with lowered presynaptic
vesicle docking (Wozniak et al., 2007; Xiao et al., 2007). The
latter effect is relevant given the altered proteins involved in vesi-
cle docking we observed here in Nrg1 HET mice. The reduced
level of FGF14 might be related to the increased expression of
GPC6 and SPARC. Glypicans are heparan sulphate proteoglycans
that act as co-receptors for growth factors and modulate fibrob-
last growth factor signaling (Paine-Saunders et al., 1999; Galli
et al., 2003). GPC6 has recently been identified as a gene that
confers susceptibility to formal thought disorder in schizophre-
nia and as a factor released from astrocytes that supports the
formation of glutamatergic synapses via GluA1 AMPA recep-
tors (Allen et al., 2012; Wang et al., 2012). Similar to GPC6,
SPARC is released from astrocytes and modulates the formation
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FIGURE 2 | Adolescent hippocampal proteomics comparing
adolescent WT mice treated with vehicle and THC.
(A) Representative 2DE gel images showing positions of significantly
altered protein spots, the horizontal axis split by isoelectric point,
vertical axis split by molecular weight; [CALB2 (spot 11103); ARL1
(spot 11677); GSTM2 (spot 11418); HSPA4 (spot 11769)]; and (B)
Exemplar normalized volumes of altered proteins i.e., CALB2, ARL1,
and GSTM2.
of excitatory synapses and FGF expression (Kucukdereli et al.,
2011; Bradshaw, 2012). Taken together these findings suggest a
novel link between Nrg1 and other interrelated growth factor-
related proteins FG14, GPC6, and SPARC, worthy of further
examination in future studies.
The hippocampus of adolescent Nrg1 HET mice displayed
altered expression of various proteins that influence cell survival
and neuroinflammation including AVEN, ABIN2, and RGS10.
Nrg1 exerts neuroprotective effects via inhibiting apoptosis trig-
gered by various challenges (Chen et al., 2011; Li et al., 2012;
Woo et al., 2012). AVEN inhibits apoptosis (Chau et al., 2000;
Figueroa et al., 2004; Kutuk et al., 2010), therefore the reduction
of AVEN in the hippocampus of Nrg1 HET mice might con-
fer greater vulnerability to apoptosis in these mice. Adolescent
Nrg1 HET mice displayed a trend toward increased expression of
the pro-apoptotic and inflammatory cytokine TNF-α in the hip-
pocampus and schizophrenia patients with a missense mutation
in the transmembrane domain ofNRG1 show heightened expres-
sion of TNF-α from B cells (Marballi et al., 2010; Desbonnet et al.,
2012). This is interesting as ABIN-2 and RGS10, two proteins
altered in Nrg1 HET mice, modulate the action of the TNF-α.
ABIN-2 prevents TNF-α mediated pro-apoptotic effects and its
decreased expression in Nrg1 HET mice might reflect again a
greater propensity to hippocampal apoptosis (Verstrepen et al.,
2009). Perhaps as a compensatory mechanism Nrg1 HET mice
showed increased expression of RGS10, a protein which renders
cells resistant to TNF-α induced apoptosis (Lee et al., 2012).
Future studies are required to confirm whether altered apoptosis
and neuroinflammation exists in Nrg1 HET mice.
DIFFERENTIAL EFFECTS OF THC ON THE PROTEOME OF Nrg1 HET MICE
vs. WT MICE
Our prior research shows that Nrg1 heterozygotes display an
altered neurobehavioral response to cannabinoids (Boucher et al.,
2007a,b, 2011; Arnold et al., 2012; Long et al., 2013).Nrg1mutant
mice were more sensitive to the behavioral actions of acute
THC compared to WT littermates in a sex-specific manner, with
males being selectively affected but not females (Boucher et al.,
2007a; Long et al., 2010). In a repeated dosing study, tolerance to
cannabinoid-induced hypothermia and locomotor suppression
developed more rapidly in Nrg1 HET than WT mice (Boucher
et al., 2011). Conversely, only WT mice developed tolerance to
cannabinoid-induced anxiety and Nrg1 HET mice maintained a
persistent anxiogenic response to repeated cannabinoid exposure.
Acute and repeated cannabinoid exposure selectively activated
expression of Fos transcription factors in the lateral septum of
Nrg1 HET mice but not WT mice (Boucher et al., 2007b, 2011).
We also examined whether Nrg1 hypomorphism confers vul-
nerability to the neurobehavioral actions of acute or repeated
THC exposure in adolescence (Long et al., 2013). THC exposure
exacerbated the hyperlocomotor phenotype of Nrg1 HET mice
expressed after withdrawal of the drug. Further, repeated THC
administration also promoted differential effects on CB1 receptor,
5-HT2A and NMDA receptor binding. Notably adolescent THC
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FIGURE 3 | Adolescent hippocampal proteomics comparing
adolescent Nrg1 HET mice treated with vehicle and THC.
(A) Representative 2D E gel images showing positions of significantly
altered protein spots (the horizontal axis split by isoelectric point,
vertical axis split by molecular weight; [GPSM2 (spot 11713); APOA1
(spot 11674); NAPEPLD (spot 11060); OTOR (spot 12395)]; and
(B) exemplar normalized volumes of altered proteins i.e., GPSM2,
APOA1 and NAPEPLD.
FIGURE 4 | Schematic representation of altered proteins. (A) Proteins with different expression in Nrg1 HET mice relative to WT controls; and (B) Proteins
with different expression in THC administered Nrg1 HET mice relative to vehicle treated controls.
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exposure selectively increased NMDA receptor expression in the
hippocampus of Nrg1 HET but not WT mice. Given these find-
ings it is perhaps not surprising that the impact of repeated THC
treatment as measured by proteomics was quite distinct in Nrg1
HETmice vs.WTmice, with no overlap in differentially expressed
proteins Table 3.
Nevertheless, our findings show some degree of overlap with
previous examinations of THC effects on the rodent brain pro-
teome (Quinn et al., 2008; Colombo et al., 2009; Rubino et al.,
2009a; Filipeanu et al., 2011; Wang et al., 2011). THC treatment
in adolescent rats modulated proteins regulating oxidative stress
such as glutathione S-transferase and heat shock proteins (Quinn
et al., 2008). Our results replicate the finding that repeated THC
exposure decreased the expression of GSTM2 in the hippocam-
pus (Quinn et al., 2008). GSTM2 catalysis the conjugation of
reduced glutathione to electrophilic compounds thereby reduc-
ing the deleterious effects of reactive oxygen species (ROS) on
cellular lipid, protein and DNA. By reducing levels of GSTM2,
THC may render the hippocampus more vulnerable to oxida-
tive stress and this may be linked to the long-term memory
impairing effects of cannabinoids (Quinn et al., 2008; Boucher
et al., 2009). Phencyclidine, another drug of abuse that promotes
schizophrenia-relevant behaviors and cognitive dysfunction, also
reduced glutathione levels and antioxidant defense enzymes in
the rodent brain (Radonjic et al., 2010; Stojkovic´ et al., 2012).
Interestingly, copy number variants in genes encoding glutathione
S-transferase may be involved in susceptibility to schizophre-
nia (Rodriguez-Santiago et al., 2010). Here we also showed
repeated adolescent THC exposure upregulated the expression of
heat shock protein 70 kDa in the hippocampus. Previous studies
illustrated effects of rodent THC exposure on heat shock pro-
tein 70 kDa, heat shock cognate 71 kDa protein and heat shock
60 kDa protein (Bindukumar et al., 2008; Quinn et al., 2008;
Colombo et al., 2009; Rubino et al., 2009a; Filipeanu et al.,
2011). Heat shock proteins regulate cellular stress responses and
provide protection against oxidative stress (Quinn et al., 2008;
Stetler et al., 2010) so their increased expression may signify
greater oxidative stress in the hippocampus. Heat shock pro-
tein 70 kDa may also serve an autophagic function facilitating
the clearance of toxic proteins and assisting in neuronal survival
(Stetler et al., 2010).
Adolescent THC exposure decreased hippocampal levels of
the calcium-binding protein CALB2. CB1 receptors are expressed
on calretinin-positive GABA interneurons in the hippocampus
(Marsicano and Lutz, 1999; Morozov et al., 2009). THC expo-
sure in C57/BL6 mice increased expression of this protein in the
cerebellum (Colombo et al., 2009). Colombo et al. (2009) ana-
lyzed CALB2 expression in the membrane whereas we assessed
the cytosolic fraction, therefore it remains possible our find-
ing may reflect translocation of the protein from the cytosol
to the membrane. We isolated a novel protein, (ARL1), which
was downregulated in response to THC exposure. Alcohol and
methamphetamine administration similarly alter expression of
this protein (Iwazaki et al., 2008; Kobeissy et al., 2008; Kashem
et al., 2009). ARL1 is a Ras GTPase involved in retrograde
trafficking of endosomes between the Golgi apparatus and the
membrane in mammalian cells (Nishimoto-Morita et al., 2009). Ta
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A THC-induced reduction in ARL1 may then disrupt the distri-
bution of intracellular protein transport in the hippocampus.
Proteins selectively altered in Nrg1 HET mice treated with
THC include those that affect synapse formation and the dynam-
ics of dendritic spines. Nrg1 is a neurotrophic factor involved in
spinogenesis through its modulation of NMDA receptor function
(Li et al., 2007; Chen et al., 2008; Barros et al., 2009; Bennett,
2011; Nason et al., 2011). Adolescent THC exposure reduced
the density of dendritic spines in the hippocampus via mod-
ulation of a number of proteins important to spine dynamics
such as PSD-95 and NMDA receptors (Rubino et al., 2009b).
Nrg1 hypomorphism might abnormally increase dendritic spine
density in the hippocampus in response to THC as adolescent
Nrg1 HET mice treated with THC displayed increased NMDA
receptor binding in the hippocampus (Long et al., 2013). Our
proteomic findings indicate altered expression in a number of
proteins involved in intracellular trafficking and stabilization of
NMDA receptors at the synapse. These include FLOT1, APOA1,
and GPSM2.
GPSM2 traffics intracellular NMDA receptors to the synap-
tic membrane and facilitates spinogenesis by forming a macro-
molecular complex with NMDA receptors and synapse associated
protein 102 (Sans et al., 2005). The reduced level of GPSM2 we
observed in THC-treated Nrg1 HET mice may reflect GPSM2
being incorporated into the macromolecular complex, lowering
the observed expression of free, unconjugated GPSM2. Further,
Nrg1 HET mice treated with THC showed a selective increase
in FLOT1 expression in the hippocampus, a protein that helps
stabilize lipid rafts in the membrane. FLO T1 mediates neurite
branching and dendritic spine dynamics in the hippocampus
(Swanwick et al., 2010; Raemaekers et al., 2012). It also regu-
lates the formation of glutamatergic synapses and interacts with
NMDA receptors, possibly to enhance NMDA receptor clustering
or trafficking to the membrane (Allen et al., 2007; Swanwick et al.,
2009, 2010). Lipid rafts are constituted by cholesterol and sphin-
golipids (Mauch et al., 2001; Hering et al., 2003). APOA1, a pro-
tein that stimulates cholesterol release from glia, was upregulated
in THC exposed Nrg1 HETmice (Hirsch-Reinshagen et al., 2004;
Karten et al., 2005). Therefore, APOA1, by increasing the avail-
ability of cholesterol for incorporation into lipid rafts, may have in
turn assisted in the molecular events required to stabilize NMDA
receptors at the synaptic membrane. Interestingly, APOA1 is
altered in schizophrenia brain (Huang et al., 2008).
The increased excitatory transmission mediated by increased
NMDA receptors in THC-treated Nrg1 HET mice might also
increase the expression of the apoptotic marker PCD2 and
anandamide synthesizing enzyme NAPEPLD (Howlett et al.,
2011), proteins reflecting heightened excitotoxicity/apoptosis and
a homeostatic attempt to dampen increased NMDA receptor
activation respectively. These results are consistent with Nrg1-
cannabinoid interactions dysregulating the septohippocampal
system. Increased excitation in the hippocampus of THC-treated
Nrg1 HET mice might then influence downstream activity of the
lateral septum, a region we have repeatedly shown to be selectively
activated in Nrg1 HET mice in response to THC (Boucher et al.,
2007b, 2011).
CONCLUSIONS
Using a proteomic approach we have uncovered numerous novel
proteins that may be subject to regulation by disturbed Nrg1
signaling. Our findings also illuminate a potential constellation
of molecular changes that may subserve the behavioral abnor-
malities that are observed in the Nrg1 transmembrane domain
heterozygous mouse as well as their idiosyncratic response to
repeated cannabinoid treatment. This may have implications for
our overall understanding of genetic vulnerability to schizophre-
nia and to the exacerbation of psychosis sometimes caused by
cannabis.
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